Release Date: May 01, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Alphatec Holdings Inc (NASDAQ:ATEC) reported a strong start to 2025 with a 22% revenue growth and 24% surgical growth, significantly outperforming the market.
• The company achieved $11 million in adjusted EBITDA, marking its second-best quarter ever and exceeding expectations.
• Surgical revenue grew by 24% year-over-year, driven by a 17% increase in procedural volume and an 18% rise in surgeon adoption.
• Alphatec Holdings Inc (NASDAQ:ATEC) ended the first quarter with $153 million in cash and access to an additional $60 million in available borrowing, reinforcing its financial stability.
• The company successfully refinanced its 2026 convertible note, extending maturity to 2030 and maintaining a low coupon rate, providing financial flexibility.

Negative Points

• Non-GAAP gross margin decreased by 50 basis points compared to the previous year, primarily due to product mix.
• The company faced modest and transient working capital headwinds, impacting cash flow performance.
• Tariff exposure is expected to impact the cost of goods sold in the low single-digit millions, primarily affecting EOS units imported from France.
• Despite strong revenue growth, the company still experienced a cash burn of $15 million in the first quarter.
• Alphatec Holdings Inc (NASDAQ:ATEC) is still in the early phases of its international expansion, with significant growth potential yet to be realized in markets like Japan.

Q & A Highlights

• Warning! GuruFocus has detected 7 Warning Signs with ATEC.

Q: Can you provide insights into the market potential and competitive dynamics for the new corpectomy system? A: Pat Miles, CEO: The market valuation is challenging, but we are unique in offering the procedure in the prone position, which provides access to both the front and back of the spine. This approach is advantageous for instability cases, often due to tumors or trauma. Our system's engineering, including the retractor and implant, is outstanding, and it integrates well with our other technologies like MEPs from SafeOp.

Q: How does the tariff exposure impact your financials, and what percentage of your products are affected? A: Todd Koning, CFO: The tariff exposure is limited to our EOS equipment and related parts, manufactured in France and imported to the US. We estimate the impact to be in the low single-digit millions, affecting our cost of goods sold primarily in the second half of the year. Our implant business is not directly affected by tariffs.

Q: Could you update us on the robot launch plans and its integration into the company's strategy? A: Pat Miles, CEO: The robot launch is on track for the end of the year. We are in the alpha phase, focusing on ensuring the workflow efficiency. The navigation piece is crucial, and we aim to integrate it seamlessly into our procedures without disrupting the workflow. The robot will enhance our procedural efficiency, particularly in stabilization workflows.

Q: Can you discuss the cash flow trends and what gives you confidence in achieving your cash flow goals for the year? A: Todd Koning, CFO: We achieved a $15 million cash use in Q1, at the low end of our guidance. We expect Q2 to range from $0 to $5 million, with positive cash flow in Q3 and Q4. Our confidence is bolstered by improved working capital metrics, better-than-expected adjusted EBITDA, and enhanced asset utilization.

Q: How is the sales force performing, particularly the reps recruited in recent years? A: Pat Miles, CEO: The sales force is evolving, with reps transitioning to more proprietary sales over time. We are seeing geographic variations in sales types, and our sets are being used more efficiently. We are gaining access to academic institutions, which enhances our market presence. Overall, we are still in the early stages of building meaningful sales force density.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.